POLFA WARSZAWA S.A.
POLFA WARSZAWA S.A., a prominent player in the pharmaceutical industry, is headquartered in Warsaw, Poland. Established in 1945, the company has a rich history marked by significant milestones in the development and production of high-quality medicinal products. Specialising in the manufacture of generic pharmaceuticals, POLFA WARSZAWA offers a diverse portfolio that includes both prescription and over-the-counter medications. Their commitment to innovation and quality sets them apart in a competitive market, ensuring that they meet the evolving needs of healthcare providers and patients alike. With a strong presence in Central and Eastern Europe, POLFA WARSZAWA S.A. has solidified its position as a trusted name in pharmaceuticals, recognised for its dedication to excellence and patient care. The company continues to expand its reach, contributing to the advancement of healthcare solutions across the region.
DitchCarbon Score
How does POLFA WARSZAWA S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
POLFA WARSZAWA S.A.'s score of 36 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
POLFA WARSZAWA S.A.'s reported carbon emissions
In 2023, POLFA WARSZAWA S.A. reported total carbon emissions of approximately 86,640,000 kg CO2e across all scopes. This includes 8,664,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 51,193,000 kg CO2e from Scope 2 emissions, primarily related to purchased electricity and steam. The company also reported significant Scope 3 emissions, totalling about 64,001,000 kg CO2e, which include emissions from the supply chain and product use. Comparatively, in 2022, POLFA's total emissions were approximately 92,483,000 kg CO2e, indicating a reduction in overall emissions in 2023. The breakdown for 2022 shows 8,783,000 kg CO2e from Scope 1, 75,086,000 kg CO2e from Scope 2, and 92,483,000 kg CO2e from Scope 3 emissions. Despite these figures, POLFA WARSZAWA S.A. has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi). The absence of defined climate pledges suggests a need for further commitment to sustainability practices within the pharmaceutical industry context. Overall, while POLFA WARSZAWA S.A. has made strides in reducing emissions, ongoing efforts and clear targets will be essential for enhancing their climate commitments and achieving long-term sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 9,022,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 81,697,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 82,440,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
POLFA WARSZAWA S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
